Vitiligo

Investigators wrote that the phenomena can be used to evaluated clinical features of the disease, resulting in more precise therapy recommendations.

Investigators reported that patients in the vitiligo group reported worse general health, and were willing to pay more than 40% of their income for a cure.

The instrument’s score was compared favorably to the Dermatology Life Quality Index and Vitiligo Impact Patient score.

Combined therapies such as ultraviolet light and tab methotrexate were deemed effective in the management of vitiligo.

Investigators believe the new instrument could be generalized to other chronic inflammatory skin diseases in future studies.

Investigators call the combination of intralesional corticosteroid injections and narrow-band ultraviolet B light to be “effective, simple, and relatively safe”.

Investigators from Egypt recorded a high prevalence of stress, anxiety, and depression in patients with vitiligo.

Dr. Lawrence Eichenfield and Dr. David Rosmarin speak to the efficacy of topical ruxolitinib displayed in several trials involving patients with atopic dermatitis and vitiligo.

Investigators also found that patients with alopecia areata were also had significant inflammatory immune injury and vitamin D deficiency when compared to healthy subjects.

Investigators incorporated a myriad of studies detailing the anxiety and depression associated with the disease, and offered new insights into the concerns of patients and caregivers.

Investigators reported that the drug helped improve skin repigmentation in patients with vitiligo, but added that further studies were needed to fully explore its efficacy.

Investigators reported a significant difference in the expansion rate of the skin lesion area in patients with vitiligo in just 3 months of treatment.

Two study authors speak on providing pediatric patients of color with atopic diseases with greater access to care.

The regulatory setback is regarding a manufacturing facility concern not associated with the investigative drug, according to the company.

In this episode of Derm Discussions, vitiligo expert John Harris, MD, PhD, discusses new tactics and therapeutic options in treating inflammatory skin disorders like vitiligo, alopecia areata, and atopic dermatitis.

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

Dr. Ezhkova and fellow investigators found that low UV exposure prompted an increase in pigmentation production through melanocytes in the body.

Dr. Chovatiya speaks on the advancements made in vitiligo research, how the disease can disproportionately impact patients of different ethnicities, and how each patient can be properly treated.

The wound care matrix is composed of hydrolyzed fish collagen infused with cod liver oil and other plant-derived oil and wax to aid in the natural wound healing process.

Investigators hope that the emerging method of managing these atopic diseases can help remove racial and socioeconomic barriers to care.

Investigators believe the treatment strategy can go on to treat other “difficult-to-treat” areas of the body such as palms, elbows, and lips.

Investigators write that methods such as dermatoscopy can result in early recognition of unstable patches and lead to appropriate medical treatment for patients with vitiligo.

A new study showed about half of all vitiligo patients from a care system were burdened with the sleeping disorder.

The COVID-19 pandemic had forced vitiligo patients to delay treatments; however, not much is known about the effects of delaying on disease course.

Patients treated with ruxolitnib cream show ≥75% improvement in facial vitiligo scoring index.